Trends in the utilization of imaging for upper tract urothelial carcinoma

被引:14
作者
Mohapatra, Anand [1 ]
Vemana, Goutham [2 ]
Bhayani, Sam [1 ]
Baty, Jack [3 ]
Vetter, Joel [1 ]
Strope, Seth A. [1 ]
机构
[1] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
[2] Urol Associates Houston, Houston, TX USA
[3] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
Upper Tract Urothelial Cancer; Imaging; Diagnosis; Endoscopy; Surgery; TRANSITIONAL-CELL-CARCINOMA; BOLUS MDCT UROGRAPHY; TOMOGRAPHY UROGRAPHY; CT UROGRAPHY; GUIDELINES; OUTCOMES;
D O I
10.1016/j.urolonc.2015.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To evaluate the changes in use of the different imaging modalities for diagnosing upper tract urothelial carcinoma (UTUC) and assess how these changes have affected tumor stage at the time of surgery. Materials and methods: We assessed the Surveillance, Epidemiology, and End Results (SEER) cancer registry and linked Medicare claims data (1992-2009) for 5377 patients who underwent surgery for UTUC. We utilized International Classification of Disease Oncology 3 codes to identify UTUC. International Classification of Disease, ninth Revision, Clinical Modification and Current Procedure Terminology codes identified surgical treatment and imaging modalities. We assessed for use of intravenous pyelography, retrograde pyelography (RGP), computed tomography urography (CTU), magnetic resonance urography (MRU), and endoscopy. For each modality, patients were categorized as having received the modality at least once or not at all. Patient characteristics were compared using chi-squared tests. Usage of imaging modalities and tumor stage was trended using Cochran-Armitage tests. We stratified our data into 2 multivariate logistic regression models to determine the effect of imaging modalities on tumor stage: 1992 to 1999 with all modalities except MRU, and 2000 to 2009 with all modalities. Results: Our patient population was predominantly White males of more than 70 years old. Intravenous pyelography and RGP declined in use (62% and 72% in 1992 vs. 6% and 58% in 2009, respectively) while computed tomography urography, MRU, and endoscopy increased in use (2%, 0%, and 37% in 1992 vs. 44%, 6%, and 66% in 2009, respectively). In both regression analyses, endoscopy was associated with lower-stage tumors. In the 2000 to 2009 model, RGP was associated with lower-stage tumors, and MRU was associated with higher-stage tumors. Finally, our data showed an increasing number of modalities utilized for each patient (1% receiving 4 modalities in 1992 vs. 20% in 2009). Conclusions: We found trends toward the utilization of newer imaging modalities to diagnose UTUC and more modalities per patient. Endoscopy and RGP were associated with smaller tumors, whereas MRU was associated with larger tumors. Further studies are needed to evaluate the utility of the different modalities in diagnosing UTUC. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:236.e23 / 236.e28
页数:6
相关论文
共 50 条
  • [31] An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database
    Browne, Brendan M.
    Stensland, Kristian D.
    Moynihan, Matthew J.
    Canes, David
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E743 - E750
  • [32] Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy
    Moschini, Marco
    Foerster, Beat
    Abufaraj, Mohammad
    Soria, Francesco
    Seisen, Thomas
    Roupret, Morgan
    Colin, Pierre
    De la Taille, Alexandre
    Peyronnet, Benoit
    Bensalah, Karim
    Herout, Roman
    Wirth, Manfred Peter
    Novotny, Vladimir
    Chlosta, Piotr
    Bandini, Marco
    Montorsi, Francesco
    Simone, Giuseppe
    Gallucci, Michele
    Romeo, Giuseppe
    Matsumoto, Kazumasa
    Karakiewicz, Pierre
    Briganti, Alberto
    Shariat, Shahrokh F.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (10) : 1541 - 1547
  • [33] Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma
    Zganjar, Andrew J.
    Thiel, David D.
    Lyon, Timothy D.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2023, 12 (09) : 1456 - 1468
  • [34] The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma
    Li, Hailong
    Zhou, Jie
    Chen, Renfu
    Zhu, Jiawei
    Wang, Junqi
    Wen, Rumin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 356e1 - 356e9
  • [35] Perioperative management of upper tract urothelial carcinoma in the Nordic countries
    Oedorf, Kimie
    Haug, Erik Skaaheim
    Liedberg, Fredrik
    Jaervinen, Riikka
    Gudjonsson, Sigurdur
    Bostroem, Peter J.
    Jerlstroem, Tomas
    Gudbrandsdottir, Gigja
    Jensen, Jorgen Bjerggaard
    Lam, Gitte Wrist
    BMC UROLOGY, 2024, 24 (01):
  • [36] Treatment of upper urinary tract urothelial carcinoma
    Cai, Guiyang
    Liu, Xuefeng
    Wu, Bin
    SURGICAL ONCOLOGY-OXFORD, 2011, 20 (01): : 43 - 55
  • [37] Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review
    Aziz, Atiqullah
    Dobruch, Jakub
    Hendricksen, Kees
    Kluth, Luis A.
    Necchi, Andrea
    Noon, Aidan
    Rink, Michael
    Roghmann, Florian
    Seiler, Roland
    Gontero, Paolo
    Kassouf, Wassim
    Shariat, Shahrokh F.
    Xylinas, Evanguelos
    WORLD JOURNAL OF UROLOGY, 2017, 35 (09) : 1401 - 1407
  • [38] Molecular aspects of upper tract urothelial carcinoma
    Patel, Nilay
    Arya, Manit
    Muneer, Asif
    Powles, Tom
    Sullivan, Mark
    Hines, John
    Kelly, John
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 28.e11 - 28.e20
  • [39] Endoscopic Treatment of Upper Tract Urothelial Carcinoma
    Verges, Daniel P.
    Lallas, Costas D.
    Hubosky, Scott G.
    Bagley, Demetrius H., Jr.
    CURRENT UROLOGY REPORTS, 2017, 18 (04)
  • [40] Endoscopic management of upper tract urothelial carcinoma
    Polcari, Anthony J.
    Hugen, Cory M.
    Turk, Thomas M.
    CANADIAN JOURNAL OF UROLOGY, 2009, 16 (06) : 4887 - 4894